Mary Dolan to Cell Proliferation
This is a "connection" page, showing publications Mary Dolan has written about Cell Proliferation.
Connection Strength
1.140
-
Mixed effects modeling of proliferation rates in cell-based models: consequence for pharmacogenomics and cancer. PLoS Genet. 2012 Feb; 8(2):e1002525.
Score: 0.234
-
Population differences in the rate of proliferation of international HapMap cell lines. Am J Hum Genet. 2010 Dec 10; 87(6):829-33.
Score: 0.216
-
Identification of genomic regions contributing to etoposide-induced cytotoxicity. Hum Genet. 2009 Mar; 125(2):173-80.
Score: 0.189
-
Susceptibility loci involved in cisplatin-induced cytotoxicity and apoptosis. Pharmacogenet Genomics. 2008 Mar; 18(3):253-62.
Score: 0.178
-
A genome-wide approach to identify genetic variants that contribute to etoposide-induced cytotoxicity. Proc Natl Acad Sci U S A. 2007 Jun 05; 104(23):9758-63.
Score: 0.169
-
Heritable and non-genetic factors as variables of pharmacologic phenotypes in lymphoblastoid cell lines. Pharmacogenomics J. 2010 Dec; 10(6):505-12.
Score: 0.051
-
Population-specific genetic variants important in susceptibility to cytarabine arabinoside cytotoxicity. Blood. 2009 Mar 05; 113(10):2145-53.
Score: 0.047
-
Genetic variants associated with carboplatin-induced cytotoxicity in cell lines derived from Africans. Mol Cancer Ther. 2008 Sep; 7(9):3038-46.
Score: 0.046
-
Somatic acquisition and signaling of TGFBR1*6A in cancer. JAMA. 2005 Oct 05; 294(13):1634-46.
Score: 0.009